These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 30030356)

  • 1. Proceedings of the 2017 Viral Clearance Symposium, Session 2.1: DSP Unit Operations-Virus Filtration/Inactivation.
    Kreil TR; Roush D
    PDA J Pharm Sci Technol; 2018; 72(5):470-478. PubMed ID: 30030356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Use of Bayesian Hierarchical Logistic Regression in the Development of a Modular Viral Inactivation Claim.
    Banton D; Vacante D; Bulthuis B; Goldstein J; Wineburg M; Schreffler J
    PDA J Pharm Sci Technol; 2019; 73(6):552-561. PubMed ID: 31101710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proceedings of the 2017 Viral Clearance Symposium, Session 6: Ensuring Viral Safety in Continuous Processing.
    Johnson SA; Roush D
    PDA J Pharm Sci Technol; 2018; 72(5):516-524. PubMed ID: 30030352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proceedings of the 2017 Viral Clearance Symposium Session 5: Facility Risk Mitigation.
    Ma J; Kreil TR
    PDA J Pharm Sci Technol; 2018; 72(5):511-515. PubMed ID: 30030359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proceedings of the 2019 Viral Clearance Symposium, Session 6: Virus-Retentive Filtration.
    O'Donnell S; Bolton G
    PDA J Pharm Sci Technol; 2022; 76(4):349-357. PubMed ID: 34911825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.
    Radomski KU; Lattner G; Schmidt T; Römisch J
    BioDrugs; 2017 Apr; 31(2):125-134. PubMed ID: 28236170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of various processing steps for viral clearance of therapeutic proteins: database analyses of commonly used steps.
    Cipriano D; Burnham M; Hughes JV
    Methods Mol Biol; 2012; 899():277-92. PubMed ID: 22735960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proceedings of the 2009 Viral Clearance Symposium.
    Miesegaes G; Bailey M; Willkommen H; Chen Q; Roush D; Blümel J; Brorson K
    Dev Biol (Basel); 2010; 133():3-101. PubMed ID: 21516942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proceedings of the 2017 Viral Clearance Symposium, Session 2.2: DSP Unit Operations-Purification Unit Operations.
    Roush D; Kreil TR
    PDA J Pharm Sci Technol; 2018; 72(5):479-487. PubMed ID: 30030354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proceedings of the 2019 Viral Clearance Symposium, Session 5: Viral Inactivation.
    Ma J
    PDA J Pharm Sci Technol; 2022; 76(4):339-348. PubMed ID: 34911831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proceedings of the 2017 Viral Clearance Symposium, Session 1.2: Upstream Mitigation, Part 2-Virus Barrier Filter and HTST.
    Chen D; Bolton G
    PDA J Pharm Sci Technol; 2018; 72(5):462-469. PubMed ID: 30030355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity.
    Poelsler G; Berting A; Kindermann J; Spruth M; Hämmerle T; Teschner W; Schwarz HP; Kreil TR
    Vox Sang; 2008 Apr; 94(3):184-192. PubMed ID: 18167162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.
    Barone PW; Avgerinos S; Ballard R; Brussel A; Clark P; Dowd C; Gerentes L; Hart I; Keumurian FJ; Kindermann J; Leung JC; Ly N; Mink S; Minning S; Mullberg J; Murphy M; Nöske K; Parriott S; Shum B; Wiebe ME; Springs SL
    PDA J Pharm Sci Technol; 2019; 73(2):191-203. PubMed ID: 30361281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achieving a Successful Scale-Down Model and Optimized Economics through Parvovirus Filter Validation using Purified TrueSpikeTM Viruses.
    De Vilmorin P; Slocum A; Jaber T; Schaefer O; Ruppach H; Genest P
    PDA J Pharm Sci Technol; 2015; 69(3):440-9. PubMed ID: 26048749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proceedings of the 2019 Viral Clearance Symposium, Session 1: Viral Clearance Strategies and Case Studies.
    Reitz S; Schwantes A
    PDA J Pharm Sci Technol; 2022; 76(4):297-305. PubMed ID: 34911829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Process scale considerations in evaluation studies and scale-up.
    Walter JK; Werz W; Berthold W
    Dev Biol Stand; 1996; 88():99-108. PubMed ID: 9119169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma.
    Goussen C; Simoneau S; Bérend S; Jehan-Kimmel C; Bellon A; Ducloux C; You B; Paolantonacci P; Ollivier M; Burlot L; Chtourou S; Flan B
    BioDrugs; 2017 Jun; 31(3):251-261. PubMed ID: 28508264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.
    Troccoli NM; McIver J; Losikoff A; Poiley J
    Biologicals; 1998 Dec; 26(4):321-9. PubMed ID: 10403036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation and Removal of Chikungunya Virus and Mayaro Virus from Plasma-derived Medicinal Products.
    Yue C; Teitz S; Miyabashi T; Boller K; Lewis-Ximenez LL; Baylis SA; Blümel J
    Viruses; 2019 Mar; 11(3):. PubMed ID: 30866548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Session 1.1: Viral Clearance Using Traditional, Well-Understood Unit Operations: Low pH and Detergent Viral Inactivation.
    Ma J; Roush D
    PDA J Pharm Sci Technol; 2016 Sep; 70(5):410-416. PubMed ID: 27516488
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.